FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2577124890> ?p ?o ?g. }

• W2577124890 endingPage "14924" @default.
• W2577124890 startingPage "14912" @default.
• W2577124890 abstract "Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive non-Hodgkin lymphomas. It is curable but one-third of cases are refractory to therapy or relapse after initial response highlighting the urgent need for developing novel therapeutic approaches. Targeting sirtuins, particularly SIRT1 by genetic approaches or using pharmaceutical inhibitor tenovin-6, has shown promising therapeutic potential in various hematopoietic malignancies. However, it remains unknown whether these approaches are effective for DLBCL. In this study, we have found that tenovin-6 potently inhibits the proliferation and survival of DLBCL cells. Surprisingly, specific knockdown of SIRT1/2/3 has no effect on DLBCL. Mechanistically, tenovin-6 increases the level of microtubule-associated protein 1 light chain 3B (LC3B)-II in a SIRT1/2/3- and p53-independent manner in DLBCL cell lines. Tenovin-6-mediated increase of LC3B-II is through inhibition of classical autophagy pathway. Furthermore, inhibition of the autophagy pathway by using other inhibitors or by knocking down key genes in the pathway impairs cell proliferation and survival of DLBCL cells. These results indicate that targeting the autophagic pathway could be a novel therapeutic strategy for DLBCL and that precaution should be taken to interpret data where tenovin-6 was used as an inhibitor of sirtuins." @default.
• W2577124890 created "2017-01-26" @default.
• W2577124890 creator A5010896860 @default.
• W2577124890 creator A5036607488 @default.
• W2577124890 creator A5040405172 @default.
• W2577124890 creator A5046156970 @default.
• W2577124890 creator A5052521552 @default.
• W2577124890 creator A5054150116 @default.
• W2577124890 creator A5063042101 @default.
• W2577124890 date "2017-01-19" @default.
• W2577124890 modified "2023-10-14" @default.
• W2577124890 title "Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy" @default.
• W2577124890 cites W1414516785 @default.
• W2577124890 cites W1523693806 @default.
• W2577124890 cites W1613566907 @default.
• W2577124890 cites W1931704533 @default.
• W2577124890 cites W1948872103 @default.
• W2577124890 cites W1965765787 @default.
• W2577124890 cites W1971209012 @default.
• W2577124890 cites W1971448178 @default.
• W2577124890 cites W1982605681 @default.
• W2577124890 cites W1983204997 @default.
• W2577124890 cites W1984371096 @default.
• W2577124890 cites W1992659717 @default.
• W2577124890 cites W1998319919 @default.
• W2577124890 cites W1998943082 @default.
• W2577124890 cites W2020789296 @default.
• W2577124890 cites W2025099161 @default.
• W2577124890 cites W2025523323 @default.
• W2577124890 cites W2028608234 @default.
• W2577124890 cites W2033986030 @default.
• W2577124890 cites W2035405658 @default.
• W2577124890 cites W2038831537 @default.
• W2577124890 cites W2041486896 @default.
• W2577124890 cites W2045122835 @default.
• W2577124890 cites W2045970460 @default.
• W2577124890 cites W2047390792 @default.
• W2577124890 cites W2050547186 @default.
• W2577124890 cites W2051018605 @default.
• W2577124890 cites W2056936324 @default.
• W2577124890 cites W2060929195 @default.
• W2577124890 cites W2065116481 @default.
• W2577124890 cites W2068753140 @default.
• W2577124890 cites W2070224555 @default.
• W2577124890 cites W2071754840 @default.
• W2577124890 cites W2073762029 @default.
• W2577124890 cites W2077397852 @default.
• W2577124890 cites W2083919459 @default.
• W2577124890 cites W2088431383 @default.
• W2577124890 cites W2096882254 @default.
• W2577124890 cites W2097117077 @default.
• W2577124890 cites W2101345691 @default.
• W2577124890 cites W2107646677 @default.
• W2577124890 cites W2109681644 @default.
• W2577124890 cites W2114560798 @default.
• W2577124890 cites W2122212799 @default.
• W2577124890 cites W2122587601 @default.
• W2577124890 cites W2125988618 @default.
• W2577124890 cites W2128681673 @default.
• W2577124890 cites W2139939518 @default.
• W2577124890 cites W2140513990 @default.
• W2577124890 cites W2140854963 @default.
• W2577124890 cites W2147246240 @default.
• W2577124890 cites W2150382709 @default.
• W2577124890 cites W2156210428 @default.
• W2577124890 cites W2161234475 @default.
• W2577124890 cites W2164778558 @default.
• W2577124890 cites W2174370490 @default.
• W2577124890 cites W2197446758 @default.
• W2577124890 cites W2283262789 @default.
• W2577124890 cites W2291198447 @default.
• W2577124890 cites W2310358028 @default.
• W2577124890 cites W2313781640 @default.
• W2577124890 cites W2322645003 @default.
• W2577124890 cites W2524142464 @default.
• W2577124890 cites W2586808754 @default.
• W2577124890 cites W2883994141 @default.
• W2577124890 cites W296713146 @default.
• W2577124890 cites W4231526733 @default.
• W2577124890 doi "https://doi.org/10.18632/oncotarget.14741" @default.
• W2577124890 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5362454" @default.
• W2577124890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28118604" @default.
• W2577124890 hasPublicationYear "2017" @default.
• W2577124890 type Work @default.
• W2577124890 sameAs 2577124890 @default.
• W2577124890 citedByCount "21" @default.
• W2577124890 countsByYear W25771248902017 @default.
• W2577124890 countsByYear W25771248902018 @default.
• W2577124890 countsByYear W25771248902019 @default.
• W2577124890 countsByYear W25771248902020 @default.
• W2577124890 countsByYear W25771248902021 @default.
• W2577124890 countsByYear W25771248902022 @default.
• W2577124890 countsByYear W25771248902023 @default.
• W2577124890 crossrefType "journal-article" @default.
• W2577124890 hasAuthorship W2577124890A5010896860 @default.
• W2577124890 hasAuthorship W2577124890A5036607488 @default.
• W2577124890 hasAuthorship W2577124890A5040405172 @default.
• W2577124890 hasAuthorship W2577124890A5046156970 @default.

• next